Discontinued — last reported Q4 '25
Products & Services · Sales
Remicade — Sales
Over 4 years (FY 2021 to FY 2025), Remicade — Sales shows a downward trend with a -100.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryMarket Position
SignalLower is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ4 2025
Rolls up toTotal Revenue
How to read this metric
A decrease in sales signals the expected decline of a mature product facing generic or biosimilar competition, while stability or unexpected growth may indicate successful lifecycle management or slower-than-anticipated market erosion.
Detailed definition
This metric represents the total revenue generated from the sale of the biologic drug Remicade within the company's phar...
Peer comparison
Comparable to revenue metrics for legacy pharmaceutical products or off-patent drugs in the portfolios of major biopharmaceutical peers.
Metric ID:
mrk_segment_remicade_salesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $150.00M | $146.00M | $132.00M | $122.00M | $106.00M | $98.00M | $88.00M | $102.00M | $96.00M | $90.00M | $86.00M | $78.00M | $70.00M | $82.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | -2.7% | -9.6% | -7.6% | -13.1% | -7.5% | -10.2% | +15.9% | -5.9% | -6.3% | -4.4% | -9.3% | -10.3% | +17.1% | -100.0% | — | — | — | — |
| YoY Change | — | — | — | — | -29.3% | -32.9% | -33.3% | -16.4% | -9.4% | -8.2% | -2.3% | -23.5% | -27.1% | -8.9% | -100.0% | -100.0% | -100.0% | -100.0% | — |
Range$0.00 – $150.00M
CAGR-100.0%
Avg YoY Growth-42.2%
Median YoY Growth-28.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s remicade — sales?
- Merck & Co. (MRK) reported remicade — sales of $0.00 in Q4 2025.
- What is the long-term trend for Merck & Co.'s remicade — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s remicade — sales has grown at a -100.0% compound annual growth rate (CAGR), from $598.00M to $0.00.
- What does remicade — sales mean?
- The total annual revenue generated from the sale of the drug Remicade.